Global Molecular Breast Imaging (MBI) Market, By Application (Detection, Diagnosis, Others), End User (Hospitals and Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Research Centers) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In the recent years, molecular breast imaging (MBI) has been widely deployed for diagnostic or imaging purposes, along with thermography and ultrasound, among others. Various key players are making use of a host of technologies and tools for detecting, diagnosing and screening breast cancer. Breast imaging has become sought-after for detecting blood flow and tissue composition.
Molecular breast imaging is considered one of the painless and standard additional test to assess areas of concern among radiologists. Global Molecular Breast Imaging (MBI) Market is expected to witness a CAGR of 10.00% during the forecast period of 2022-2029. “Hospitals” accounts for the most prominent end user segment in the respective market owing to the rise in the number of cancer cases. The market report curated by DBMR research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Breast imaging refers to one of the subspecialties of diagnostic radiology. This diagnostic technology uses either ionizing or non-ionizing radiation. In the case of molecular breast imaging, the ionizing radiation is used for detecting tumor lesion in breasts. Clinicians use the technology to carry out early detection even before the symptoms appear.
Report Scope and Market Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Application (Detection, Diagnosis, Others), End User (Hospitals and Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Research Centers) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
|
Market Players Covered |
Koninklijke Philips N.V. (Netherlands), Hitachi Ltd. (Japan), Siemens Healthcare GmbH (Germany), CANON MEDICAL SYSTEMS CORPORATION (Japan), General Electric (US), Aspect Imaging Ltd (Israel), Bruker (US), Aurora Health Care (US), FONAR Corp. (US), ESAOTE SPA (Italy), Neusoft Corporation (China), TOSHIBA CORPORATION (Japan), Sanrad Medical Systems Private Limited (India), FUJIFILM Holdings Corporation (Japan), ONEX Corporation (Canada), Hologic, Inc. (US), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Imaging Diagnostic Systems, Inc. (US), Agfa-Gevaert Group (Belgium), and Koning Health (China), among others |
|
Market Opportunities |
|
Molecular Breast Imaging (MBI) Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:
- Prevalence of Breast Cancer
The increase in the prevalence of breast cancer among women population across the globe acts as one of the major factors driving the growth molecular breast imaging (MBI) market. With the increase in the cases of cancer, the demand for enhanced diagnostics and treatment is rising.
- Continuous Support for Cancer Research
The continuous support for cancer research from the public and private sectors in the form of funds and investments accelerate the market growth.
- Research and Development
The surge in the number of research and development activities to enhance the treatment options available further influence the market. The advancement in the technology declines the acquisition time and offers high sensitivity and specifity.
Opportunities
Furthermore, contract-based diagnostic solutions and mobile solutions extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, technological development will further expand the market.
Restraints/Challenges
On the other hand, high cost associated with the molecular breast imaging (MBI) and stringent regulatory approval procedures are expected to obstruct market growth. Also, side effects of radiation exposure and Errors in breast cancer screening and diagnosis are projected to challenge the molecular breast imaging (MBI) market in the forecast period of 2022-2029.
This molecular breast imaging (MBI) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on molecular breast imaging (MBI) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Covid-19 Impact on Molecular Breast Imaging (MBI) Market
COVID-19 had both positive and negative impact on the molecular breast imaging (MBI) market. The decline in the productivity in life science organizations during the pandemic impacted the market. However, MBI emerged as a great potential in the improvement and management of COVID-19 that accelerated the demand for molecular breast imaging (MBI). The market is expected to witness health growth post-pandemic as well owing to its application in combating various other epidemics in the future.
Recent Development
- AuntMinnie.com partnered with Delphinus Medical Technologies Inc. to relaunch Imaging Leaders Community with backed by the breast imaging company in February’2022. Delphinus created the SoftVue 3D Whole Breast Ultrasound Tomography System that assists in screening asymptomatic women having dense tissue.
Global Molecular Breast Imaging (MBI) Market Scope and Market Size
The molecular breast imaging (MBI) market is segmented on the basis of applications and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
- Detection
- Diagnosis
- Others
On the basis of application, the molecular breast imaging (MBI) market is segmented into detection, diagnosis and others.
End User
- Hospitals and Clinics
- Diagnostic Centers
- Ambulatory Surgical Centers
- Research Centers
On the basis of end user, the molecular breast imaging (MBI) market is segmented into hospitals and clinics, diagnostic centers, ambulatory surgical centers, and research centers. Hospitals dominates the end user segment owing to the rise in the number of hospitals throughout the globe.
Molecular Breast Imaging (MBI) Market Regional Analysis/Insights
The molecular breast imaging (MBI) market is analysed and market size insights and trends are provided by country, applications and end user as referenced above.
The countries covered in the molecular breast imaging (MBI) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the molecular breast imaging (MBI) market because of the high prevalence of breast cancer among women and rise in awareness about breast cancer within the region. Also, technological advancements, and the presence of major manufacturers further expands the market.
Asia-Pacific (APAC) is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increase in the target patient population, and government initiatives to improve health care facilities in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The molecular breast imaging (MBI) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for molecular breast imaging (MBI) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the molecular breast imaging (MBI) market. The data is available for historic period 2010-2020.
Competitive Landscape and Molecular Breast Imaging (MBI) Market Share Analysis
The molecular breast imaging (MBI) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to molecular breast imaging (MBI) market.
Some of the major players operating in the molecular breast imaging (MBI) market are:
- Koninklijke Philips N.V. (Netherlands)
- Hitachi Ltd. (Japan)
- Siemens Healthcare GmbH (Germany)
- CANON MEDICAL SYSTEMS CORPORATION (Japan)
- General Electric (US)
- Aspect Imaging Ltd (Israel)
- Bruker (US),
- Aurora Health Care (US)
- FONAR Corp. (US)
- ESAOTE SPA (Italy)
- Neusoft Corporation (China)
- TOSHIBA CORPORATION (Japan)
- Sanrad Medical Systems Private Limited (India)
- FUJIFILM Holdings Corporation (Japan)
- ONEX Corporation (Canada)
- Hologic, Inc. (US)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
- Imaging Diagnostic Systems, Inc. (US)
- Agfa-Gevaert Group (Belgium)
- Koning Health (China)
SKU-
